ClinicalTrials.gg
TerminatedNCT00427154Updated Sep 5, 2018

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

A Phase 3 interventional study of rosiglitazone and inhaled human insulin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 103 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-05.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
21st of 51
227 · median 149
Started
2007
with 2 others
Phase 3
21 of 52
none open now
Registered
33rd of 52
by date
Lead sponsor
4 of 52
Novo Nordisk A/S

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2007, is one of 21 in phase 3, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin or rosiglitazone treatment, both in combination with metformin and glimepiride.

Read the detailed description

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 227 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Currently treated with antidiabetes drugs (including Exenatide) for at least 2 months
  • between 7.5 and 11.0% (both inclusive) on antidiabetes combination therapy
  • less than or equal to 40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Current smoking or smoking within the last 6 months
  • Current acute or chronic pulmonary disease (except for asthma)
  • Proliferative retinopathy requiring acute treatment
  • disease history including kidney or liver disease
  • Heart disease which limits physical activity or results in discomfort with physical activity
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
227 participants (actual)

Study arms

  • Active comparator
    A

    Drug: inhaled human insulin · Drug: metformin · Drug: glimepiride

  • Active comparator
    B

    Drug: rosiglitazone · Drug: metformin · Drug: glimepiride

Interventions

07

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Time frame: After 26 weeks

Secondary outcomes

  1. Fasting plasma glucose

    Time frame: For the duration of the trial

  2. Lipid profiles

    Time frame: For the duration of the trial

  3. Hypoglycaemic episodes

    Time frame: For the duration of the trial

  4. Glucose profiles

    Time frame: For the duration of the trial

  5. Change in body weight

    Time frame: For the duration of the trial

08

Study locations

103 sites
  • Novo Nordisk Investigational Site
    Hueytown, Alabama 35023, United States
  • Novo Nordisk Investigational Site
    Ozark, Alabama 36360, United States
  • Novo Nordisk Investigational Site
    Tuscaloosa, Alabama 35406, United States
  • Novo Nordisk Investigational Site
    Vestavia Hills, Alabama 35209, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85741, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Huntington Beach, California 92646, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Orange, California 92869, United States
  • Novo Nordisk Investigational Site
    Poway, California 92064, United States
  • Novo Nordisk Investigational Site
    Roseville, California 95661, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95821, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92103, United States
  • Novo Nordisk Investigational Site
    Santa Barbara, California 93105, United States
  • Novo Nordisk Investigational Site
    Temecula, California 92591, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80904, United States
  • Novo Nordisk Investigational Site
    Waterbury, Connecticut 06708, United States
  • Novo Nordisk Investigational Site
    Boca Raton, Florida 33433, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33759, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33010, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33021, United States
  • Novo Nordisk Investigational Site
    Lake Mary, Florida 32746, United States
  • Novo Nordisk Investigational Site
    Marianna, Florida 32446, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Merritt Island, Florida 32953, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33136, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33029, United States
  • Novo Nordisk Investigational Site
    Vero Beach, Florida 32960, United States
  • Novo Nordisk Investigational Site
    West Palm Beach, Florida 33401, United States
  • Novo Nordisk Investigational Site
    Athens, Georgia 30606, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30342, United States
  • Novo Nordisk Investigational Site
    Augusta, Georgia 30912-3152, United States
  • Novo Nordisk Investigational Site
    Dunwoody, Georgia 30338, United States
  • Novo Nordisk Investigational Site
    Powder Springs, Georgia 30127, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Suwanee, Georgia 30024, United States
  • Novo Nordisk Investigational Site
    Tucker, Georgia 30084, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Boise, Idaho 83702, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Peoria, Illinois 61615, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62711, United States
  • Novo Nordisk Investigational Site
    Lafayette, Indiana 47904, United States
  • Novo Nordisk Investigational Site
    Des Moines, Iowa 50314, United States
  • Novo Nordisk Investigational Site
    Shawnee Mission, Kansas 66204, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Wichita, Kansas 67205, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Scarborough, Maine 04074, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21201, United States
  • Novo Nordisk Investigational Site
    Marlborough, Massachusetts 01752, United States
  • Novo Nordisk Investigational Site
    Springfield, Massachusetts 01199, United States
  • Novo Nordisk Investigational Site
    Jackson, Mississippi 39216, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Jefferson City, Missouri 65109, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64111, United States
  • Novo Nordisk Investigational Site
    Saint Louis, Missouri 63141, United States
  • Novo Nordisk Investigational Site
    Billings, Montana 59101, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68114, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89109, United States
  • Novo Nordisk Investigational Site
    Berlin, New Jersey 08009, United States
  • Novo Nordisk Investigational Site
    Cherry Hill, New Jersey 08034, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Staten Island, New York 10301, United States
  • Novo Nordisk Investigational Site
    Syracuse, New York 13210, United States
  • Novo Nordisk Investigational Site
    Asheville, North Carolina 28803, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28209, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    High Point, North Carolina 27262, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45245, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44115, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44122, United States
  • Novo Nordisk Investigational Site
    Dayton, Ohio 45406, United States
  • Novo Nordisk Investigational Site
    Dayton, Ohio 45439, United States
  • Novo Nordisk Investigational Site
    Clinton, Oklahoma 73601, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73104-5020, United States
  • Novo Nordisk Investigational Site
    Medford, Oregon 97504-8491, United States
  • Novo Nordisk Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Novo Nordisk Investigational Site
    Beaver, Pennsylvania 15009, United States
  • Novo Nordisk Investigational Site
    Norristown, Pennsylvania 19401, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Clarksville, Tennessee 37043, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Arlington, Texas 76014, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    Hurst, Texas 76054, United States
  • Novo Nordisk Investigational Site
    Lewisville, Texas 75067, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Arlington, Virginia 22204, United States
  • Novo Nordisk Investigational Site
    Norfolk, Virginia 23502, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23249, United States

Showing the first 100 of 103 sites. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2007 to primary completion in Mar 2008, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2007
First posted
Jan 26, 2007
StartActual
Jan 10, 2007
Primary completionActual
Mar 11, 2008
CompletionActual
Mar 11, 2008
Results delay requested
Sep 3, 2018
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00427154
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 26, 2007
Start date
Jan 10, 2007
Primary completion
Mar 11, 2008
Completion
Mar 11, 2008
Last update
Sep 5, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Insulin, Regular, Human

Start the discussion